Clinical trial
High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia [HD-LIPT]
NCT01205035 is registered in ClinicalTrials.gov with Eye Center of Northern Colorado, P.C. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia [HD-LIPT]
- Lead sponsor
- Eye Center of Northern Colorado, P.C.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2010
- Completion date
- October 31, 2012
- Enrollment
- 6 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.